GH1 and obesity due to melanocortin 4 receptor deficiency: A recent meta-analysis of human studies examining the efficacy and safety of recombinant GH as therapy for obesity [87] concluded that rhGH therapy leads to decrease in visceral adiposity and increase in lean body mass without inducing weight loss.